Bringing drugs to market is notoriously time-consuming and expensive. Small companies are uniquely positioned to change that.
As Congress considers a bill that aims to distance U.S. biopharma from five Chinese companies, the industry must emphasize ...
The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...
Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand ...
In October 2023, Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological ...
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as ...
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...
Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for ...
Thursday’s announcement comes after the insurance giant last week said it would remove AbbVie’s Humira from its major ...
If approved in chronic obstructive pulmonary disease, Nucala will compete with Verona’s Ohtuvayre and—pending a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback